Comparison of the Efficacy of Hemoadsorption Combined With Hemodialysis of Different Treatment Durations in Clearing Protein-Bound Uremic Toxins: A Randomized Crossover Controlled Trial
This is an open-label, randomized, crossover study to evaluate the efficacy of extending the duration of hemoadsorption (HA) combined with hemodialysis (HD) from 2 hours to 4 hours for clearing protein-bound uremic toxins, such as Indoxyl Sulfate (IS), in stable maintenance hemodialysis patients. Patients will be randomized to receive either 2-hour HA or 4-hour HA once a week for 8 weeks, then cross over to the other treatment for another 8 weeks after a 2-week washout period. The primary endpoint is the reduction rate of IS.
• Age between 18 and 75 years, regardless of gender
• Stable maintenance hemodialysis for ≥3 months, with a relatively fixed dialysis regimen
• Receiving hemodialysis 3 times per week, each session lasting ≥4 hours
• Single-pool Kt/V (spKt/V) ≥1.2 within 8 weeks prior to enrollment
• Willing and able to sign the informed consent form